Stacy L. Chin explains that SBIR reviewers fund the commercialization plan, not just the science. A clear path to market or patient use matters from your first application, not later. Integrate commercial strategy into your proposal from day one.
Great science gets reviewers interested, but commercialization is what gets you funded. One of the biggest misconceptions among first-time applicants is that commercialization only matters in Phase II and beyond, and that simply is not true. Reviewers want to know how the technology works, if there's a realistic path to getting it in the hands of customers or patients. Commercialization isn't just a separate idea from the science, it's actually the reason why the science matters in your SBIR grant. So start thinking about commercialization from day one, not after you get funded.
Applying for NIH SBIR in Jan 5, 2027? You Should Be Starting NOW. Here's why...
How to Get Invited to Apply for $305K in NSF SBIR Funding || Step-by-Step Guide
